Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.uca.edu.ar/handle/123456789/13681
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Reiter, R. | es |
dc.contributor.author | Sharma, Ramaswamy | es |
dc.contributor.author | Simko, Fedor | es |
dc.contributor.author | Domínguez Rodriguez, Alberto | es |
dc.contributor.author | Tesarik, Jan | es |
dc.contributor.author | Neel, Richard L. | es |
dc.contributor.author | Slominski, Andrzej T. | es |
dc.contributor.author | Kleszczynsk, Konrad | es |
dc.contributor.author | Martin‑Gimenez, Verna M. | es |
dc.contributor.author | Manucha, Walter | es |
dc.contributor.author | Cardinali, Daniel Pedro | es |
dc.date.accessioned | 2022-03-25T12:19:36Z | - |
dc.date.accessioned | 2022-03-25T12:19:46Z | - |
dc.date.available | 2022-03-25T12:19:36Z | - |
dc.date.available | 2022-03-25T12:19:46Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Reiter, R. et al. Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection [en línea]. Cellular and Molecular Life Sciences. 2022, 79 (143). doi: 10.1007/s00018-021-04102-3. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/13681 | es |
dc.identifier.uri | https://repositorio.uca.edu.ar/handle/123456789/13681 | - |
dc.description.abstract | Abstract: Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efcacy in preventing or treating this serious condition and all have side efects to difering degrees. We encourage the continued consideration of the use of the antioxidant and anti-infammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientifc publications have identifed melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral efects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous diferent viruses, including three diferent coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most efective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profle over a wide range of doses and lacks signifcant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially benefcial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2. | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Springer | es |
dc.rights | Acceso abierto | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.source | Cellular and Molecular Life Sciences. 2022, 79 (143) | es |
dc.subject | CITOQUINAS | es |
dc.subject | INFECCIONES | es |
dc.subject | COVID-19 | es |
dc.subject | CORONAVIRUS | es |
dc.subject | SEPSIS | es |
dc.subject | HIPOXIA | es |
dc.title | Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.1007/s00018-021-04102-3 | - |
dc.contributor.orcid | 0000-0001-6763-4225 | - |
uca.disciplina | MEDICINA | es |
uca.issnrd | 1 | es |
uca.affiliation | Fil: Reiter, R. Universidad de Texas. Departamento de Sistemas Celulares y Anatomía; Estados Unidos | es |
uca.affiliation | Fil: Sharma, Ramaswamy. Universidad de Texas. Departamento de Sistemas Celulares y Anatomía; Estados Unidos | es |
uca.affiliation | Fil: Simko, Fedor. Universidad Comenius. Facultad de Medicina. Instituto de Fisiopatología; República Eslovaca | es |
uca.affiliation | Fil: Domínguez Rodriguez, Alberto. Hospital Universitario de Canarias. Departamento de Cardiología; España | es |
uca.affiliation | Fil: Tesarik, Jan. Clínica MAR&Gen; España | es |
uca.affiliation | Fil: Neel, Richard L. Alcasian Care Enterprises; Estados Unidos | es |
uca.affiliation | Fil: Slominski, Andrzej T. Universidad de Alabama. Departamento de Dermatología; Estados Unidos | es |
uca.affiliation | Fil: Kleszczynsk, Konrad. Universidad de Münster. Departamento de Dermatología; Alemania | es |
uca.affiliation | Fil: Martin‑Gimenez, Verna M. Universidad Católica de Cuyo. Facultad de Cs. Químicas Y Tecnológicas. Instituto de Investigaciones en Ciencias Químicas; Argentina | es |
uca.affiliation | Fil: Manucha, Walter. Universidad Católica de Cuyo. Facultad de Cs. Químicas Y Tecnológicas. Instituto de Investigaciones en Ciencias Químicas; Argentina | es |
uca.affiliation | Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina | es |
uca.version | publishedVersion | es |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Consejo Nacional de Investigaciones Científicas y Técnicas | - |
crisitem.author.dept | Instituto de Investigaciones Biomédicas - BIOMED | - |
crisitem.author.dept | Facultad de Ciencias Médicas | - |
crisitem.author.orcid | 0000-0002-0813-9088 | - |
crisitem.author.parentorg | Facultad de Ciencias Médicas | - |
crisitem.author.parentorg | Pontificia Universidad Católica Argentina | - |
Aparece en las colecciones: | Artículos Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
melatonin-highlighting-use.pdf | 1,26 MB | Adobe PDF | Visualizar/Abrir |
Visualizaciones de página(s)
77
comprobado en 16-abr-2024
Descarga(s)
55
comprobado en 16-abr-2024
Google ScholarTM
Consultar
Altmetric
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons